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Abstract  
Background: There is a weak relationship between subjective symptoms and 
objective markers of disease activity in individuals with Primary Sjögren’s Syndrome 
(PSS). This presents a significant barrier to developing treatments if modifying 
disease markers does not translate into reduced perception of symptoms. Little is 
known about the reasons for this discrepancy. 
 
Objectives: To develop a novel method for capturing the discrepancy between 
objective tests and subjective dryness symptoms (a ‘Sensitivity’ scale) and to explore 
predictors of dryness Sensitivity. 
 
Methods: Archive data from the UK Primary Sjogren’s Syndrome Registry (n=681) 
was used. Patients were classified on a scale from -5 (stoical) to +5 (sensitive) 
depending on the degree of discrepancy between their objective and subjective 
symptoms classes. Sensitivity scores were correlated with demographic variables, 
disease-related factors and symptoms of pain, fatigue, anxiety and depression.  
 
Results: Patients were on average relatively stoical for both dryness symptoms 
(ocular mean±s.d. -0.42±2.2, oral mean±s.d. -1.24±1.6). Twenty-seven percent of 
patients were classified ‘sensitive’ to ocular dryness in contrast to 9% for oral 
dryness. Hierarchical regression analyses identified the strongest predictor of ocular 
dryness was self-reported pain and the strongest predictor of oral dryness was self-
reported fatigue. 
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Conclusions: Ocular and oral dryness sensitivity can be classified on a continuous 
scale. The two symptom types are predicted by different variables. A large number 
of factors remain to be explored that may impact on symptom-sensitivity in PSS and 
the proposed method could be used to identify relatively sensitive and stoical 
patients for future studies. 
 
Key words: 
Primary Sjögren’s Syndrome, dryness symptoms, subjective objective discrepancy, 
Schirmer’s I Test, Unstimulated Salivary Flow 
 
 
 
Significance and Innovations: 
 Outlines a novel method for defining concordance between objective signs and 
subjective symptoms that is independent of units of measurement 
 The method is able to identify both stoical individuals (high objective signs, low 
subjective symptoms) and sensitive individuals (low objective signs, high 
subjective symptoms) 
 We explored factors predicting symptom sensitivity – pain and fatigue symptoms 
were the biggest predictors of sensitivity to ocular and oral dryness respectively 
 A large proportion of variance in symptom sensitivity remains unexplained – this 
method could be used in future studies to identify sensitive individuals and 
investigate a larger number of predictive factors (including further biological and 
psychological measures) 
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Primary Sjögren’s Syndrome (PSS) is an autoimmune disorder of unknown aetiology 
which is characterised by dry eyes and dry mouth and is associated with 
extraglandular systemic symptoms such as fatigue, pain (myalgia and polyarthralgia) 
and autonomic dysfunction (1). It has an estimated prevalence of 0.01 - 0.09% (2) 
and is more common in women (9:1 female:male ratio (3)). The condition has a 
marked negative impact on health-related quality of life and social functioning (4) 
The medications used to improve extraglandular symptoms are less effective in 
treating sicca symptoms (5). An important factor in understanding and treating these 
is the weak association between the results of objective clinical tests of tear or saliva 
production and the severity of self-report dryness symptoms.  This is reflected in the 
current America European Consensus Group (AECG) classification criteria, which 
dictate that a PSS diagnosis is made when individuals fulfil four or more of the 
established criteria, which include both subjective and objective items  (6). 
Understanding the discrepancy between objective and subjective findings may be of 
importance for improving research into the condition. 
Several studies have indicated weak correlations between objective and subjective 
indices of ocular dryness (7-15). Although the majority of these studies found that 
subjective symptoms are generally worse with increased objective severity, two 
observed that subjective symptoms were better as the objective severity measure 
increased (7, 15), which may relate to reduced sensation resulting from greater 
damage to the eye (7). In contrast, the relationship between subjective and objective 
oral dryness measures seems to be stronger (16-21), although there are some 
individuals suffering from subjective xerostomia who display no objective salivary 
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gland dysfunction (17). 
Discrepancies between objective and subjective symptoms create a number of 
dilemmas for clinicians. For example, patients may not receive optimal treatment 
(those with abnormal test results but few subjective symptoms may be ‘under-
treated’, whereas those with normal test results but high subjective symptoms may 
receive interventions that are unlikely to help). Furthermore it becomes difficult to 
interpret (lack of) response to treatment, which could be particularly important in 
clinical trials of novel therapeutic agents. It is therefore of interest to explore this 
relationship in greater depth. The path from pathological change in tissues to 
perceived distressing symptoms is complex and dependent on a number of factors 
both relating to the severity of the underlying disease as well as concomitant 
psychosocial factors including low mood and anxiety (22-26). Developing a method 
to differentiate patients on the basis of their sensitivity to symptoms could aid 
research into the factors that contribute to variability in the distress and disability 
caused by PSS and ultimately could contribute to the stratification of patients for 
particular management pathways. 
The present study develops a novel method to define the degree of 
concordance/discrepancy between objective and subjective findings. This will be 
used to investigate the relationship between subjective symptoms and objective 
measures of dry eyes and mouth in people with PSS to identify factors associated 
with symptom sensitivity.  
Patients and Methods 
 
Participants 
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The present study uses archive data from 688 patients on the United Kingdom 
Primary Sjögren's Syndrome Registry database (UKPSSR, www.sjogrensregistry.org), 
who were recruited across 30 hospital sites from August 2009 to March 2012 (for full 
details see (27)). All patients fulfilled the AECG classification criteria (6). Patients 
gave written informed consent to participate and National Health Service ethical 
approval was granted for this study from North West – Haydock National Research 
Ethics Service committee. 
Measures  
Patient-Reported Measures  
Subjective symptoms were assessed using the European League Against Rheumatism 
(EULAR) Sjögren’s Syndrome Patient Reported Index (ESS PRI) sicca scores. This is a 
validated self-report measure of ocular and oral dryness symptoms (28, 29). Patients 
rated their symptoms over the past two weeks on a 0-10 scale (10=maximum 
imaginable dryness). In addition, there were also items that measured subjective 
fatigue, mental fatigue and pain. Patients also self-reported their medication use and 
comorbidities. 
Psychosocial factors  
The EuroQol 5 Dimensions 3 Levels (EQ-5D-3L) (30) was used to measure quality of 
life (QoL). This includes a simple Visual Analogue Scale (VAS) and a Time Trade Off 
value (TTO). Lower values indicate better quality of life. 
Depression and anxiety were measured using the Hospital Anxiety and Depression 
scales (HADS) (31). 
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Clinician-reported Assessment Measures 
The ESS Disease Activity Index (DAI) (29, 32)  and Disease Damage Index (DDI) (33) 
were used to assess the extent of systemic disease activity and damage respectively.  
Ocular dryness 
Schirmer I test: A sterile strip of filter paper was inserted inside the patient’s lower 
eyelid for 5 minutes after which, the level of wetting was measured using a 
standardised ruler. The average result of both eyes was then calculated. Participants 
were asked not to use eye-drops for 2 hours prior to testing. Lower scores indicate 
abnormal tear production and a score of ≤5mm/5min is considered severe by AECG 
criteria (6). 
Oral dryness 
Unstimulated Salivary Flow (USF): the patient was required to spit saliva into a 
graduated test tube every minute. This was conducted under normal room 
temperature and humidity and participants were asked not to eat/drink/smoke for 
at least 2 hours beforehand. According to AECG criteria, a quantity of ≤1.5ml 
collected over 15 minutes indicates impaired saliva secretion (6).  
Defining Discordance 
The present study used a modified discordance measure that was based on Delbaere 
et al. (34)(2010). Subjective symptom severity and objective test result severity for 
both ocular and oral dryness were split into classes. Patients’ subjective ocular and 
oral dryness severities (based on ESS PRI item scores) were grouped into 
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asymptomatic (scoring 0) and symptomatic groups (5 equal classes; see Table 1). 
Objective test result severities were grouped into the same number of classes. As no 
formal severity “grading” is available for either the Schirmer’s test or USF results, 
reasonable severity “grading” cut-offs, supported by the expert consensus of a 
consultant rheumatologist, were established for the purposes of this study and test 
results were grouped into equal severity classes as shown in Table 1. The severe 
class cut-offs, for both Schirmer and USF tests, are as close as possible to the 
diagnostic cut-offs used by the AECG criteria. 
The subjective severity classes for ocular and oral dryness were then cross -tabulated 
with the corresponding objective severity class in order to identify each patient’s 
degree of sensitivity for ocular and oral dryness. This was completed using the 
sensitivity grid shown in table 1. 
The degree of disparity between subjective symptoms and objective test results was 
given an arbitrary value and conceptualised on a continuous Sensitivity scale (see 
figure 1). On the scale a value of 0 signifies full concordance, with negative values 
indicating increasing stoicism and positive values indicating increasing sensitivity. 
Patients were grouped into ‘sensitive’ (a positive sensitivity score), ‘accurate’ (a 
score of 0), and stoical (a negative sensitivity score). 
Analysis 
Analyses were performed using IBM SPSS/PC software version 21. Pairwise deletions 
for missing data were employed. One-way ANOVA with post-hoc least significant 
difference tests were used to compare groups, using α=0.05. Proportion data 
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between groups was compared with chi-square tests, with any significant overall 
difference followed-up with pairwise comparisons with a Bonferroni-adjusted p-
value of p=0.05/3=0.017. Bivariate Spearman correlations were used to explore the 
relationships between objective and subjective measures and between Sensitivity 
and demographic variables, disease- and treatment-related factors, and self- and 
clinician-rated symptoms. The strength of correlations was compared using Fisher’s r 
to z transformation. Linear stepwise hierarchical multiple regression was used to 
explore the predictors of Sensitivity. Variables were entered stepwise in the 
following sequence of blocks: 1) demographics and disease factors (age, gender, 
symptom duration, disease damage index, number of comorbidities, number of 
medications, number of xerogenic medications, use of a lachrymal/saliva substitute) , 
2) Other symptoms and quality of life (fatigue, mental fatigue, pain, anxiety, 
depression and quality of life visual analogue scale). The criteria for entry into the 
model was p<0.05 and for exit p>0.1. Separate regressions were run for ocular and 
oral sensitivity. Only the results for the variables appearing in the final model are 
reported. 
Results 
Participant characteristics and scores on the measures are reported in table 3. The 
majority of the sample was female (n=651 (95%)). Lachrymal and saliva substitutes 
were used by 544 (79.1%) and 305 (44.3%) participants respectively. Two hundred 
and ninety five participants (42.9%) were taking at least one xerogenic medication.  
Subjective vs Objective Symptoms 
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A weak but significant correlation (r=-0.13, p=0.001) was found between ocular 
dryness and Schirmer test results. A moderate correlation (r=-0.31, p<0.001) was 
found between oral dryness and USF test results. The directions of the relationships 
indicate that increasing symptom severity was associated with reduced tear and 
saliva production. Objective and subjective results were significantly more strongly 
correlated for oral dryness than ocular dryness (z=3.47, p<0.001). 
Symptom Severity and Sensitivity 
Table 1 shows the proportion of patients falling into the 6 severity classes on each of 
the objective measures. Forty-six percent of patients were in the most severe range 
for the Schirmer test and 77% for unstimulated salivary flow, indicating markedly 
reduced saliva production was more common than markedly reduced tear 
production. Sixteen percent of patients were in what we have defined as the 
‘normal’ range for the Schirmer test compared with only 4% for unstimulated 
salivary flow. Cross-tabulating ocular and oral severity gradings showed that only 
eight people (1.2%) were in the ‘normal’ range on both measures, whereas 268 
(39.4%) were in the most severe classification for both. In this sample, a high 
proportion of patients had severe symptoms on at least one objective test measure.  
A level of discordance (i.e. a Sensitivity score other than zero) was observed in 80.9% 
and 73.7% of the participants for ocular and oral dryness respectively. Mean ocular 
Sensitivity was -0.42 (s.d.=2.2) and mean oral Sensitivity was -1.24 (s.d.=1.6), 
indicating on average patients were relatively stoical for both dryness symptoms. 
Fewer patients scored in the sensitive range (score ≥+1) for oral dryness (n=59, 8.7%) 
than ocular dryness (n= 178, 26.8%). This is partly related to differences in the 
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severity of objective results – the majority of patients had severely reduced saliva 
production, and therefore could not score in the sensitive range. 
Sensitivity for ocular and oral dryness were positively correlated (r = 0.35, p <0.001), 
indicating that a higher sensitivity for ocular dryness was associated with higher 
sensitivity for oral dryness. 
Factors influencing ocular and oral dryness sensitivity 
Table 3 reports means by group for selected factors that might contribute to 
symptom sensitivity. The pattern was very similar for both ocular and oral sensitivity. 
There were no significant differences in total number of comorbidities, but oral-
stoical patients were taking significantly fewer medications (of any type) than 
accurate patients (p=0.002). For both types of symptom sensitivity, stoical patients 
showed significantly less anxiety and depression and reported significantly higher 
quality of life than both sensitive and accurate patients  (all p<0.05). There were no 
significant differences in anxiety and depression between the sensitive and accurate 
group (all p>0.05). There was a significant difference between the groups in the self-
reported presence of functional conditions, with the sensitive group reporting a 
significantly higher incidence of both fibromyalgia and irritable bowel syndrome than 
the stoical group (all p<0.017). Oral-sensitive patients reported a significantly higher 
incidence of irritable bowel syndrome than accurate patients (p=0.003), but 
otherwise there were no further significant differences between the sensitive and 
accurate groups. There were no significant differences between the groups in the 
proportion of those with any Diagnostic and Statistical Manual- or International 
Classification of Disease-defined mental illness (all p>0.05). 
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To explore other factors associated with symptom sensitivity, Spearman’s bivariate 
correlation results for both ocular and oral dryness Sensitivity are shown in table 4. 
Ocular Sensitivity was weakly positively correlated with number of medications and 
weakly negatively correlated with age, suggesting patients taking fewer medications 
and older patients were more stoical. Oral Sensitivity was weakly positively 
correlated with number of comorbidities and number of medications, suggesting 
those with fewer comorbidities and taking fewer medications were more stoical. 
Both types of Sensitivity were moderately strongly positively correlated with patient-
rated symptoms, including fatigue, mental fatigue, pain, anxiety and depression. The 
direction of the correlations indicated that those with higher levels of these 
symptoms were more sensitive. Both types of Sensitivity were negatively correlated 
with quality of life, indicating that those with a poorer quality of life had higher 
Sensitivity scores.  
Relationship between treatment and symptom sensitivity 
To explore whether symptom sensitivity is related to treatment received, table 3 
reports the proportion of patients in the different sensitivity classes that were 
receiving particular treatments. Ocular-stoical patients were significantly less likely 
to be receiving a medication known to cause dryness than sensitive patients 
(p=0.004), and whilst there was an overall group difference for oral sensitivity, post-
hoc tests did not show any significant differences between the groups. There were 
no significant differences between the groups in use of at least one symptomatic 
treatment for dryness or pilocarpine (all p>0.218). However, oral-stoics were 
significantly less likely to be using a saliva substitute (40.1%) than accurate patients 
 15 
(56.4%; p<0.001) and there was no significant difference between stoical and 
sensitive patients (43.1%; p=0.660). Similarly for ocular sensitivity, ocular-stoics were 
significant less likely than accurate patients to have received the more invasive 
treatments of punctal plugging or cauterisation (18.8% vs 33.8%; p=0.012) and there 
were no differences with ocular-sensitive patients (22.0%; p=0.367). Ocular-sensitive 
patients were significantly less likely to be using a lachrymal substitute than both the 
accurate and stoical patients (71.5% vs 83.1% and 82.6% respectively; p=0.016 and 
p=0.002 respectively). 
Regression Analysis 
Ocular Dryness 
The final model contained six predictor variables and was statistically significant 
(F6,628=21.8, p<0.001) explaining 16.5% of the variance in sensitivity (table 4). The 
statistically significant predictors in the final model were: age, disease damage index, 
pain, fatigue and mental fatigue. Pain explained the largest additional variance (10%) 
of all the predictors, with fatigue the next highest (2.3%). Age and disease damage 
index were both negatively related to Sensitivity, indicating older patients and those 
with greater disease damage tended to be less sensitive.  
Oral Dryness 
The final model contained six predictor variables and was statistically significant 
(F6,628=24.1, p<0.001) explaining 17.9% of the variance in sensitivity (table 4). The 
statistically significant predictors in the final model were: use of a saliva substitute, 
fatigue and depression, all of which were positively associated with greater 
 16 
Sensitivity. Level of fatigue explained the largest additional variance (11.7%), 
indicating those with higher fatigue tend to be more sensitive. 
Discussion 
Replicating other work, subjective dryness symptoms and objective test results were 
only weakly correlated in patients with PSS. Using a novel method for quantifying the 
discrepancy between subjective and objective symptoms, an ordinal scale of 
symptom sensitivity was derived that ranged from stoical (self-report dryness at a 
relatively low level compared to objective findings) to accurate to sensitive (self-
report dryness at a relatively high level compared to objective findings). The majority 
of patients had a relatively stoical presentation. A significant moderate association 
was observed between ocular and oral dryness sensitivity, indicating that those who 
tended to be sensitive for ocular dryness also tended to be sensitive for oral dryness. 
Comparing sensitive, stoical and accurate patients found that stoical patients had 
lower depression and anxiety scores then the other groups, but they were also less 
likely to have received some treatments than accurate patients (saliva substitute, 
punctal plugging or cauterisation). Sensitive patients were not more likely to receive 
higher levels of intervention than accurate or stoical patients . They reported a higher 
proportion of functional conditions (fibromyalgia and irritable bowel syndrome). In 
regression analyses, symptom sensitivity was predicted by a variety of factors , but 
pain (ocular Sensitivity) and fatigue (oral Sensitivity) explained the most variance. 
As found in other studies, the relationship between subjective and objective 
measures was weaker for ocular dryness than oral dryness (35-37). Ocular dryness 
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sensitivity was predicted by higher pain and fatigue; whereas age and disease 
damage were significant negative predictors, suggesting older patients and those 
with more severe disease are relatively more stoical. Adatia et al. (7) suggested that 
symptom perception may be diminished by reduced corneal sensation due to more 
severe illness, which may explain the negative relationship with disease damage. This 
may be part of the explanation why subjective and objective ocular dryness 
measures correlate relatively more weakly - a straightforward linear relationship 
between severity of disease and severity of subjective symptoms would not be 
expected. Additionally, fewer patients objective test results fell in the severe range 
for tear production (46%) compared to saliva production (77%) and 16% had 
objectively normal tear production (compared to only 4% for saliva production), 
leaving more scope to identify ocular patients as sensitive. The symptom of 'dry eye' 
is less well-defined than ‘dry mouth’ and may be used to refer to a myriad of ocular 
sensations including burning pain, grittiness, and tired or heavy eyes. This introduces 
heterogeneity between patients in what they mean when they report dry eyes and 
not all of the experienced sensations may be expected to relate to tear production. 
As ‘dry eye’ often refers to painful sensations in the eye, this may explain why self-
report pain was the largest predictor of ocular sensitivity (but was not a significant 
predictor of oral sensitivity). 
In contrast, sensitivity to oral dryness symptoms was most strongly-associated with 
global fatigue, followed by use of a saliva substitute and number of comorbidities . It 
was not related to disease severity or pain. This suggests that different processes are 
related to symptom-sensitivity to different symptoms. 
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The overall proportion of variance explained in both regression models (16.5-17.9%) 
indicates there are explanatory factors that were not included in the present study 
which should be explored in future studies. Biological factors relating to the 
composition of the tears or saliva may be of relevance. Xerostomia can be affected 
by saliva composition (38) and multiple factors such as lachrymal secretion, corneal 
damage, tear film stability and the chemical properties of tears all jointly impact on 
the perception of ocular dryness (39). Relatively sensitive individuals could be 
targeted in future research to identify biological markers in tears or saliva that may 
impact on perceived dryness. 
Psychological models of symptom perception propose a large number of factors that 
may impact on whether someone notices a symptom (26) and could be of relevance 
to measure in PSS. Trait characteristics such as neuroticism, alexithymia (the ease 
with which one identifies emotions) and distress tolerance may play a role (40, 41). It 
has been shown that catastrophisation - a manner of thinking that exaggerates 
worries and amplifies negative consequences (42) - is highly predictive of pain 
severity in patients with PSS (43).  Similarly, greater body-focused attention may 
contribute to symptom-noticing (44) and somatosensory amplification - a 
heightened responsiveness to sensory stimulation - has been shown to contribute to 
the symptoms of many rheumatic conditions (41). Geisser et al. (45) found that 
amplification in chronic fatigue syndrome and fibromyalgia was related to higher 
clinical pain and larger numbers of comorbid somatic symptoms  and, consistent with 
this, we identified a higher proportion of patients with fibromyalgia in the sensitive 
groups. Anxiety and depression have also been shown to be significantly related to 
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greater sensitivity. In a population-based study by Anttila et al. (22), participants with 
subjective dry mouth had significantly higher frequencies of depressive symptoms. 
Similarly, Kim et al. (24) concluded that depression was associated with dry eye 
symptoms in participants with normal Schirmer test results. Additionally, social, 
contextual, cultural and interpersonal factors likely also contribute to how and 
whether patients openly discuss their symptoms with their doctor, making it difficult 
to determine whether – for stoical patients particularly – they do not experience 
distressing symptoms or they simply do not report them.  
The strengths of this study include the large sample of PSS patients and the novel 
method for defining sensitivity, which allowed potential associated variables to be 
investigated. However there are a number of limitations to acknowledge. 1) Self-
report methods are prone to response bias such as demand characteristics, social 
desirability and recall bias (46). Furthermore, when completing the self-report 
measure, participants judged the severity of their sicca symptoms against their own 
standards; however the severity of objective measures is judged against standards 
formulated from the results of many individuals  so a degree of discrepancy could be 
expected. 2) Only one objective measure of ocular and oral dryness was used. USF is 
described as the test of choice for assessing salivary secretion (20), however 
variations of methods exist for measuring ocular dryness. Whilst the Schirmer I test 
is a valid assessment, issues regarding reproducibility and sensitivity have been 
reported (47) and its use without anaesthesia (as in the present study) includes both 
basal and reflex lachrymal secretion (48), which may  exaggerate the severity of 
objective ocular dryness in those with progressive corneal desensitisation. 
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Categories of objective symptoms were derived specifically for this study in order to 
calculate the sensitivity score. Whilst the expert opinion of a consultant 
rheumatologist was used in developing the categories  and exploratory work using 
different cut-off scores or different ways of categorising patients showed the same 
pattern of relationships, the categories used here need further empirical support and 
replication in future studies to determine whether they can be operationalised and 
used clinically.  
Clinical Implications and Future Research Implications 
Going forward, we advocate the use of a measure of objective-subjective symptom 
discordance, such as outlined here, to facilitate illness stratification thereby allowing 
further research into the reasons behind this. Of particular interest are the groups 
with the greatest discordance, i.e. patients reporting severe subjective symptoms 
despite being at the milder end of the objective symptom distribution, and those 
reporting mild subjective symptoms despite being at the severe end of the objective 
distribution. An exploration of potential physical and psychological explanations is 
warranted. For example, is there a difference in pathophysiology which might 
contribute to the increased experience of mildly abnormal objective symptoms such 
as tear and saliva composition, changes in corneal sensitivity, genetic differences, 
e.g. in pain sensitivity. Conversely, there is a detailed literature on the psychological 
aspects of interoception and pain perception. Applying some of the methodologies 
from this literature to develop our understanding of the individual differences in the 
‘felt experience’ of physical symptoms would allow us to explore alternative 
treatment options, such as Cognitive Behavioural Therapy or mindfulness for those 
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with lower symptom tolerance/higher subjective symptom distress (49-51). 
Conclusion 
The study developed a novel method for determining symptom sensitivity. 
Discrepancies between objective measures and subjective symptoms were most 
strongly related to pain and fatigue; however, multiple interrelated psychological, 
pathophysiological and environmental factors are likely involved. Limitations 
associated with accurately measuring dry eyes/mouth both subjectively and 
objectively may also contribute to the observed discrepancies. Stratifying patients by 
symptom sensitivity for further research will improve our understanding of factors 
that impact on distress caused by symptoms and could open the door to non-
medication-based treatments for a subgroup of patients with the highest symptom 
sensitivity. 
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Table 1: Severity classification groups for subjective symptoms and objective results and the grid used to derive the sensiti vity score 
Objective Test Results Normal Mild  Moderate  Severe 
Schirmer I  Test (mm/5min) >14.5 
(n=109; 16%) 
11.5-14.5 
(n=40; 6%) 
8.5-11.5 
(n=37; 5%) 
5.5-8.5 
(n=67; 10%) 
2.5-5.5 
(n=120; 17%) 
<2.5 
(n=315; 46%) 
Unstimulated Salivary Flow (ml/15min) >5 
(n=26; 4%) 
4-5 
(n=8; 1%) 
3-4 
(n=9; 1%) 
2-3 
(n=42; 6%) 
1-2 
(n=74; 11%) 
<1 
(n=529; 77%) 
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0: Asymptomatic 0 -1 -2 -3 -4 -5 
1-2: Mild 1 0 -1 -2 -3 -4 
3-4 2 1 0 -1 -2 -3 
5-6: Moderate 3 2 1 0 -1 -2 
7-8 4 3 2 1 0 -1 
9-10: Severe 5 4 3 2 1 0 
 
For example, an individual with ‘severe’ objective test results (Shirmer <2.5 or saliva flow <1) but subjectively rating themselves ‘1’ – mild would 
have a discrepancy classification of -4; therefore lying at the ‘stoical’ side of the distribution. An individual subjectively reporting their 
symptoms ‘9’  -severe, while having a ‘normal ‘ objective test would score +5; the most ‘sensitive’ side of the distribution. 
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Table 2: Patient characteristics/variables  
 N Mean (SD) 
Demographics and Illness factors   
Age (years) 688  58.0 (12.5) 
Disease Duration (months) 661 80.1 (71.5) 
Symptom Duration (months) 686 152.4 (118.8) 
Symptom/Diagnosis gap (months) 659 72.7 (98.6) 
Number of Comorbidities 688 3.6 (2.5) 
Number of medications  688 5.7 (4.1) 
Patient-rated measures   
Ocular Dryness (0-10) 681 5.6  (2.8) 
Oral Dryness (0-10) 681 6.0 (2.9) 
Fatigue (0-10) 681 5.5 (2.7) 
Mental Fatigue (0-10) 680 3.9 (2.8) 
Pain (0-10) 680 4.5 (3.0) 
Quality of Life – TTO (-1.0 – 1.0) 671 0.6 (0.3) 
Quality of Life – VAS (0-100) 664 60.3 (21.4) 
HADS Anxiety (0-21) 666 8.0 (4.6) 
HADS Depression (0-21) 667 6.0 (4.0) 
Clinician-rated measures   
Disease Activity Index (0 - 123) 687 4.8 (4.9) 
Disease Damage Index (0 – 10) 688 2.5 (1.9) 
Objective Tests   
Schirmer's test (mm/5min) 671 6.2 (7.6) 
Unstimulated Salivary Flow (ml/15min) 688 0.9 (1.9) 
Sensitivity   
Ocular Sensitivity (-5 to +5) 681 -0.42 (2.2) 
Oral Sensitivity (-5 to +5) 681 -1.24 (1.6) 
SD = Standard Deviation; TTO, Time Trade Off; VAS, Visual Analogue Scale; HADS, 
Hospital Anxiety and Depression Scales 
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Table 3: Mean comorbidities, number of medications and scores for depression, anxiety and quality of life by dryness sensitivity cl assification. 
Proportions of patients in the different groups with specific comorbidities and receiving particular treatments.  
 Ocular Sensitivity Oral Sensitivity 
Stoical 
(n=351) 
Accurate 
(n=130) 
Sensitive 
(n=200) 
Comparison 
Stoical 
(n=444) 
Accurate 
(n=179) 
Sensitive 
(n=58) 
Comparison 
# Comorbidities 3.4 (2.3) 3.9 (2.5) 3.8 (2.6) F2,678=2.90, p=0.056 3.4 (2.3) 3.8 (2.6) 3.9 (2.7) F2,678=9.5, p=0.078 
# Medications 5.5 (4.1) 5.7 (3.7) 6.3 (4.2) F2,678=2.52, p=0.081 5.4 (3.9)a 6.6 (4.5)b 5.8 (3.9)a,b F2,678=4.97, p=0.007 
Anxiety (HADS) 7.3 (4.5)a 8.4 (4.8)b 8.9 (4.4)b F2,661=8.75, p<0.001 7.3 (4.4)a 9.0 (4.8)b 10.2 (4.0)b F2,661=16.45, p<0.001 
Depression (HADS) 5.3 (3.7)a 6.4 (4.3)b 6.9 (4.3)b F2,661=11.23, p<0.001 5.2 (3.6)a 7.2 (4.4)b 8.1 (4.3)b F2,661=24.00, p<0.001 
Quality of Life (VAS) 63.8(20.6)a 56.6(22.5)b 56.3(21.2)b F2,659=10.09, p<0.001 63.4(20.2) a 54.3(22.5) b 53.9(22.7) b F2,659=14.14, p<0.001 
Specific comorbidities 
Fibromyalgia (%) 6.3b 8.5a,b 14.0a Χ2(2)=9.39, p=0.009 7.0b 11.2a,b 17.2a Χ2(2)=8.08, p=0.018 
IBS (%) 5.4b 7.7a,b 12.0a Χ2(2)=7.70, p=0.021 7.7b 5.0b 17.2a Χ2(2)=9.13, p=0.010 
Mental Illness (%) 3.1 6.2 4.0 Χ2(2)=2.27, p=0.321 2.7 6.7 5.2 Χ2(2)=5.61, p=0.061 
Treatments 
Use of xerogenic medication (%) 37.3a 46.2a,b 50.0b Χ2(2)=9.14, p=0.010 39.2 48.6 51.7 Χ2(2)=6.72, p=0.035 
Use of symptomatic 
treatment for dryness (%) 97.7 96.9 97.5 Χ
2(2)=0.25, p=0.883 97.1 97.8 100.0 Χ2(2)=1.875, p=0.392 
Pilocarpine (%) 7.1 9.2 7.5 Χ2(2)=0.61, p=0.739 7.2 10.1 3.4 Χ2(2)=3.04, p=0.218 
Saliva substitute (%) - - - - 40.1a 56.4b 43.1a,b Χ2(2)=13.83, p=0.001 
Lachrymal substitute (%) 82.6b 83.1b 71.5a Χ2(2)=10.95, p=0.004 - - - - 
Punctal plugging or 
Cauterisation (%) 
18.8a 33.8b 22.0a,b Χ2(2)=12.33, p=0.002 - - - - 
#, number; HADS, Hospital Anxiety and Depression Scales; VAS, Visual Analogue Scale; IBS, Irritable Bowel Syndrome; groups wi th different 
superscripts show significant differences from one another in post-hoc tests (p<0.05 for continuous measures, p<0.017 for categorical)  
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Table 4: Spearman’s (rs) Bivariate Correlations between sensitivity 
 Ocular 
Sensitivity 
Oral 
Sensitivity 
Demographic and Illness Factors   
Age -0.11*** -0.02 
Disease Duration 0.02 0.07 
Symptom Duration -0.00 0.03 
Number of Comorbidities 0.07 0.11** 
Number of Medications 0.10** 0.12** 
Patient-rated measures   
Fatigue 0.38*** 0.39*** 
Mental Fatigue 0.33*** 0.30*** 
Pain  0.33*** 0.29*** 
Quality of Life – Time Trade Off -0.25*** -0.24*** 
Quality of Life – Visual Analogue Scale -0.21*** -0.28*** 
HADS Anxiety 0.20*** 0.26*** 
HADS Depression 0.22*** 0.30*** 
Clinician-rated Measures   
Disease Activity Index 0.02 0.03 
Disease Damage Index -0.07 0.05 
   
Oral Sensitivity 0.35***    - 
* 0.01<p≤0.05, ** 0.001<p≤0.01, ***p≤0.001 
HADS, Hospital Anxiety and Depression Scales 
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Table 5: Stepwise hierarchical regression summary for ocular dryness sensitivity and oral dryness sensitivity 
Model 
Adjusted 
R2 (%) ΔR2 (%) 
Standardised 
Beta 
Test-
statistic p 
Ocular Dryness Sensitivity      
Overall Model 16.5 - - F6,628=21.8 <0.001*** 
Age  1.3 -0.09 t634=-2.39 0.017* 
Number of medications  1.9 0.01 t634=0.25 0.802 
Disease Damage Index  0.5 -0.08 t634=-2.23 0.026* 
Pain  10.0 0.19 t634=3.89 <0.001*** 
Fatigue  2.3 0.16 t634=2.95 0.003*** 
Mental Fatigue  0.5 0.11 t634=2.14 0.033* 
      
Oral Dryness Sensitivity      
Overall Model 17.9 - - F6,628=24.1 <0.001*** 
Use of a saliva substitute - 2.9 0.15 t634=3.99 <0.001*** 
Number of comorbidities - 1.3 0.02 t634=0.43 0.667 
Age - 0.6 -0.01 t634=-0.21 0.831 
Xerogenic medications - 0.5 0.01 t634=0.24 0.812 
Fatigue - 11.7 0.30 t634=6.88 <0.001*** 
Depression - 0.9 0.13 t634=2.91 0.004*** 
* 0.01<p≤0.05, ** 0.001<p≤0.01, ***p≤0.001 
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Figure 1: Sensitivity Scale 
 
